LAVA Therapeutics NV (LAVA Therapeutics NV) Revenue per Share : $0.47 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Revenue per Share?

LAVA Therapeutics NV's revenue per share for the three months ended in Mar. 2024 was $0.26. LAVA Therapeutics NV's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.47.

Warning Sign:

LAVA Therapeutics NV revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of LAVA Therapeutics NV was -36.50% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 19.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for LAVA Therapeutics NV's Revenue per Share or its related term are showing as below:

LVTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 19.6 Med: 19.6 Max: 19.6
Current: 19.6

During the past 5 years, LAVA Therapeutics NV's highest 3-Year average Revenue Per Share Growth Rate was 19.60% per year. The lowest was 19.60% per year. And the median was 19.60% per year.

LVTX's 3-Year Revenue Growth Rate is ranked better than
72.53% of 779 companies
in the Biotechnology industry
Industry Median: 3.6 vs LVTX: 19.60

LAVA Therapeutics NV Revenue per Share Historical Data

The historical data trend for LAVA Therapeutics NV's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Revenue per Share Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue per Share

0.15

0.27

0.75

0.25

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Revenue per Share	Get a 7-Day Free Trial													0.05	0.20	-	0.01	0.26

Competitive Comparison of LAVA Therapeutics NV's Revenue per Share

For the Biotechnology subindustry, LAVA Therapeutics NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LAVA Therapeutics NV's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's PS Ratio distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's PS Ratio falls into.

LAVA Therapeutics NV Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

LAVA Therapeutics NV's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )	=	Revenue (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	6.769	/	26.733
	=	0.25

LAVA Therapeutics NV's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )	=	Revenue (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	6.992	/	26.794
	=	0.26

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.47

LAVA Therapeutics NV (NAS:LVTX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

LAVA Therapeutics NV Revenue per Share Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.